VTGN - Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst | Benzinga
Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder (SAD). Fasedienol, acquired by VTGN in 2022, is undergoing PALISADE-3/4 studies, set to conclude in 2025.
According to the analysts, SAD represents a substantial market opportunity.
Despite VTGN's current valuation, a discount compared to several CNS peers, the risk/reward ratio leans toward the upside given the ongoing fasedienol studies.
Stifel initiated coverage with a Buy rating and a price target of $12. ...